Is Evogene Ltd. (EVGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 182.4% / 30% | 216.9% / 30% | 21.1% / 30% | 11.24% / 5% | ✗ NOT HALAL |
| DJIM | 182.4% / 33% | 216.9% / 33% | 21.1% / 33% | 11.24% / 5% | ✗ NOT HALAL |
| MSCI | 32.3% / 33% | 38.4% / 33% | 3.7% / 33% | 11.24% / 5% | ✗ NOT HALAL |
| S&P | 182.4% / 33% | 216.9% / 33% | 21.1% / 33% | 11.24% / 5% | ✗ NOT HALAL |
| FTSE | 32.3% / 33% | 38.4% / 33% | 3.7% / 50% | 11.24% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -6.3% | |
| Operating Margin | -1659.9% | |
| Net Margin | -220.2% | |
| Return on Equity (ROE) | -100.7% | |
| Return on Assets (ROA) | -29.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$20M |
| Free Cash Flow | -$20M |
| Total Debt | $13M |
| Debt-to-Equity | 18.4 |
| Current Ratio | 4.5 |
| Total Assets | $40M |
Price & Trading
| Last Close | $0.82 |
| 50-Day MA | $0.92 |
| 200-Day MA | $1.15 |
| Avg Volume | 483K |
| Beta | 1.1 |
|
52-Week Range
$0.73
| |
About Evogene Ltd. (EVGN)
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop Novel Therapies for for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Evogene Ltd. (EVGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Evogene Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Evogene Ltd.'s debt ratio?
Evogene Ltd.'s debt ratio is 182.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 32.3%.
What are Evogene Ltd.'s key financial metrics?
Evogene Ltd. has a market capitalization of $8M, and revenue of $9M. The company maintains a gross margin of -6.3% and a net margin of -220.2%. Return on equity stands at -100.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.